Evidence map›Paper›PMID 32641650›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation.

Masahiko Sumi, Mari Kitahara, Tsutomu Shishido, Hiroko Kazumoto, Nozomu Uematsu, Takehiko Kirihara, Keijiro Sato, Toshimitsu Ueki, Yuki Hiroshima, Hikaru Kobayashi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Masahiko SumiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Mari KitaharaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Tsutomu ShishidoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Hiroko KazumotoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Nozomu UematsuDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Takehiko KiriharaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Keijiro SatoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Yuki HiroshimaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Nagano Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of a 53-year-old woman with prefibrotic stage primary myelofibrosis (PMF) who underwent cord blood transplantation. Nine years after transplantation, she relapsed, which was confirmed by a bone marrow examination. We decided to treat her using azacitidine. After three courses of azacitidine, a partial cytogenetic response was confirmed. Azacitidine maintenance therapy successfully maintained a low level of recipient-origin peripheral blood cells with a stable hematological condition. Azacitidine may therefore be a promising therapeutic option for PMF patients who relapse after allogeneic stem cell transplantation.

Indexed as

Antimetabolites, AntineoplasticAzacitidineCord Blood Stem Cell TransplantationFemaleHematopoietic Stem Cell TransplantationHumansMiddle AgedPrimary MyelofibrosisRecurrenceSalvage TherapyTransplantation, HomologousTreatment OutcomeAntimetabolites, AntineoplasticAzacitidineallogeneic stem cell transplantationazacitidineprimary myelofibrosisrelapse

Identifiers

PMID32641650
PMCPMC7691036
OpenAlexW3039023131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.